JP6928768B2 - 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物 - Google Patents

患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物 Download PDF

Info

Publication number
JP6928768B2
JP6928768B2 JP2017559275A JP2017559275A JP6928768B2 JP 6928768 B2 JP6928768 B2 JP 6928768B2 JP 2017559275 A JP2017559275 A JP 2017559275A JP 2017559275 A JP2017559275 A JP 2017559275A JP 6928768 B2 JP6928768 B2 JP 6928768B2
Authority
JP
Japan
Prior art keywords
minutes
pharmaceutical composition
powder
mtorr
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017559275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018503696A5 (https=
JP2018503696A (ja
Inventor
クリシュナ・バッディ
クマール・クルマッダリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syros Pharmaceuticals Inc
Original Assignee
Syros Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syros Pharmaceuticals Inc filed Critical Syros Pharmaceuticals Inc
Publication of JP2018503696A publication Critical patent/JP2018503696A/ja
Publication of JP2018503696A5 publication Critical patent/JP2018503696A5/ja
Priority to JP2021103196A priority Critical patent/JP7539855B2/ja
Application granted granted Critical
Publication of JP6928768B2 publication Critical patent/JP6928768B2/ja
Priority to JP2024135193A priority patent/JP2024161468A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017559275A 2015-02-01 2016-02-01 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物 Active JP6928768B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021103196A JP7539855B2 (ja) 2015-02-01 2021-06-22 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物
JP2024135193A JP2024161468A (ja) 2015-02-01 2024-08-14 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562110574P 2015-02-01 2015-02-01
US62/110,574 2015-02-01
US201562142709P 2015-04-03 2015-04-03
US62/142,709 2015-04-03
PCT/US2016/015917 WO2016123603A2 (en) 2015-02-01 2016-02-01 High surface-area lyophilized compositions comprising arsenic for oral administration in patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021103196A Division JP7539855B2 (ja) 2015-02-01 2021-06-22 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物

Publications (3)

Publication Number Publication Date
JP2018503696A JP2018503696A (ja) 2018-02-08
JP2018503696A5 JP2018503696A5 (https=) 2019-03-14
JP6928768B2 true JP6928768B2 (ja) 2021-09-01

Family

ID=56544541

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017559275A Active JP6928768B2 (ja) 2015-02-01 2016-02-01 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物
JP2021103196A Active JP7539855B2 (ja) 2015-02-01 2021-06-22 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物
JP2024135193A Pending JP2024161468A (ja) 2015-02-01 2024-08-14 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021103196A Active JP7539855B2 (ja) 2015-02-01 2021-06-22 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物
JP2024135193A Pending JP2024161468A (ja) 2015-02-01 2024-08-14 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物

Country Status (20)

Country Link
US (6) US10111836B2 (https=)
EP (3) EP4599823A1 (https=)
JP (3) JP6928768B2 (https=)
CN (2) CN117899029A (https=)
AU (4) AU2016211186A1 (https=)
CA (2) CA2975406C (https=)
DK (1) DK3981414T3 (https=)
ES (2) ES2899226T3 (https=)
FI (1) FI3981414T3 (https=)
HR (1) HRP20251032T1 (https=)
HU (1) HUE072537T2 (https=)
LT (1) LT3981414T (https=)
MX (2) MX390835B (https=)
PL (1) PL3981414T3 (https=)
PT (1) PT3981414T (https=)
RS (1) RS67133B1 (https=)
SI (1) SI3981414T1 (https=)
SM (1) SMT202500321T1 (https=)
TW (3) TW202337477A (https=)
WO (1) WO2016123603A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260027056A1 (en) * 2015-02-01 2026-01-29 Quetzal Therapeutics, Llc High surface-area lyophilized compositions comprising arsenic for oral administration in patients
EP4599823A1 (en) 2015-02-01 2025-08-13 Quetzal Therapeutics, LLC High surface-area lyophilized compositions comprising arsenic for oral administration in patients
ES2964979T3 (es) 2016-12-01 2024-04-10 Eupharma Pty Ltd Composiciones de arsénico
KR101844049B1 (ko) 2016-12-05 2018-03-30 주식회사 케마스 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물
KR101844050B1 (ko) 2016-12-09 2018-05-14 주식회사 케마스 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
ES3009748T3 (en) * 2017-01-18 2025-03-31 Inst Nat Sante Rech Med Pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
US12582984B1 (en) 2020-07-02 2026-03-24 Argonaut Manufacturing Services, Inc. Method for lyophilization and device thereof
US11583552B2 (en) * 2021-02-17 2023-02-21 Manoj Maniar Pharmaceutical formulation of arsenic trioxide
JP7428842B1 (ja) 2023-03-29 2024-02-06 ａｒｔｉｅｎｃｅ株式会社 活性エネルギー線硬化型インキ、その製造方法、および印刷物
WO2025172482A1 (en) * 2024-02-14 2025-08-21 Institut Gustave Roussy Oral composition of arsenic trioxide for cancer treatment

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773419A (en) 1995-03-03 1998-06-30 Falcon; Juan Method of treating cancer with tannic acid
CN1044559C (zh) * 1995-08-23 1999-08-11 哈尔滨医科大学附属第一医院 抗白血病、肝癌、淋巴瘤注射液
IL136051A0 (en) 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
US7276359B1 (en) * 1998-03-13 2007-10-02 Wyeth Polynucleotide composition, method of preparation, and use thereof
CN1131922C (zh) 1998-10-19 2003-12-24 张在喆 一种通过弹性键搭架与收拢的帐篷
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
CN1813753B (zh) * 2000-02-29 2010-04-07 布里斯托尔-迈尔斯斯奎布公司 低剂量艾替开韦制剂及其应用
AUPR874601A0 (en) * 2001-11-08 2001-11-29 Unisearch Limited Selective targeting of apoptotic cells
US7521071B2 (en) * 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
US8906422B2 (en) 2002-10-09 2014-12-09 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
GB0315632D0 (en) * 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
CN1251688C (zh) 2003-12-09 2006-04-19 重庆维特瑞医药开发有限公司 三氧化二砷冻干粉针及其生产方法
JP4292985B2 (ja) 2003-12-25 2009-07-08 Ｊｓｒ株式会社 感放射線性組成物、マイクロレンズとその形成方法および液晶表示素子
CN1698650A (zh) 2004-05-21 2005-11-23 哈尔滨伊达药业有限公司 一种治疗原发性肝癌的亚砷酸注射液及其制备方法
CN1326528C (zh) 2004-07-13 2007-07-18 东南大学 砒霜磁性纳米明胶微球的制备工艺
WO2007069272A2 (en) 2005-10-21 2007-06-21 Panacea Biotec Limited Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
WO2008046299A1 (en) * 2006-10-11 2008-04-24 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
CN101322719B (zh) * 2007-06-15 2012-03-07 杭州民生药业有限公司 一种三氧化二砷固体脂质纳米粒及其制剂
US8168224B2 (en) * 2007-12-19 2012-05-01 Beijing Shengyiyao Science & Technology Development Co., Ltd. Sodium alginate microsphere vascular embolus containing water-soluble drug and preparation and application thereof
KR101455446B1 (ko) 2008-09-19 2014-10-27 액티버스 파마 컴퍼니 리미티드 의료용 복합 유기 화합물 분체, 그 제조 방법 및 현탁액
EP2525783A1 (en) 2010-01-18 2012-11-28 Cephalon France Improved oral lysophilisates containing pvp/va
EP2359812A1 (en) 2010-01-18 2011-08-24 Cephalon France Oral lyophilised compositions
CN103142648B (zh) * 2011-12-07 2015-04-15 浙江中医药大学 一种砷化合物溶液及其制备的包载砷化合物的白蛋白纳米粒和冻干制剂
CN103408477B (zh) 2013-08-22 2015-06-10 陈鹏飞 一种含砷配位化合物及其制备方法
PL3250213T3 (pl) 2015-01-29 2023-10-30 Eupharma Pty Ltd Kompozycje zawierające arsen do stosowania w sposobach leczenia
EP4599823A1 (en) 2015-02-01 2025-08-13 Quetzal Therapeutics, LLC High surface-area lyophilized compositions comprising arsenic for oral administration in patients

Also Published As

Publication number Publication date
LT3981414T (lt) 2025-09-25
NZ772450A (en) 2024-07-05
HRP20251032T1 (hr) 2025-10-24
AU2023214307A1 (en) 2023-08-31
CN107530373B (zh) 2023-12-29
MX390835B (es) 2025-03-21
SI3981414T1 (sl) 2025-10-30
MX2020012611A (es) 2021-02-09
US20200060974A1 (en) 2020-02-27
HK1248113A1 (zh) 2018-10-12
US20160235679A1 (en) 2016-08-18
US12364664B2 (en) 2025-07-22
DK3981414T3 (da) 2025-07-14
US20230310325A1 (en) 2023-10-05
US10111836B2 (en) 2018-10-30
AU2021203752A1 (en) 2021-07-08
US20210069115A1 (en) 2021-03-11
EP3981414B1 (en) 2025-06-25
US10653628B2 (en) 2020-05-19
ES3034734T3 (en) 2025-08-22
TW202337477A (zh) 2023-10-01
SMT202500321T1 (it) 2025-11-10
WO2016123603A3 (en) 2016-11-03
AU2016211186A1 (en) 2017-08-17
US10272045B2 (en) 2019-04-30
TWI790191B (zh) 2023-01-21
CN117899029A (zh) 2024-04-19
EP3250214A2 (en) 2017-12-06
JP7539855B2 (ja) 2024-08-26
WO2016123603A2 (en) 2016-08-04
US20190029963A1 (en) 2019-01-31
CA2975406C (en) 2025-07-22
EP3250214A4 (en) 2018-09-19
TW202228734A (zh) 2022-08-01
HUE072537T2 (hu) 2025-11-28
EP3250214B1 (en) 2021-09-01
EP4599823A1 (en) 2025-08-13
JP2021152059A (ja) 2021-09-30
TW201642879A (zh) 2016-12-16
NZ734201A (en) 2024-03-22
US20240269076A1 (en) 2024-08-15
CA3225480A1 (en) 2016-08-04
MX2017009913A (es) 2018-08-15
CN107530373A (zh) 2018-01-02
CA2975406A1 (en) 2016-08-04
FI3981414T3 (fi) 2025-07-29
AU2021203752B2 (en) 2023-08-31
AU2023214307B2 (en) 2025-08-21
AU2025259861A1 (en) 2025-11-20
JP2018503696A (ja) 2018-02-08
PL3981414T3 (pl) 2025-10-06
PT3981414T (pt) 2025-07-22
JP2024161468A (ja) 2024-11-19
RS67133B1 (sr) 2025-09-30
EP3981414A1 (en) 2022-04-13
ES2899226T3 (es) 2022-03-10

Similar Documents

Publication Publication Date Title
JP6928768B2 (ja) 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物
Derakhshandeh et al. Active targeting carrier for breast cancer treatment: Monoclonal antibody conjugated epirubicin loaded nanoparticle
KR20210005714A (ko) 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법
US20220280469A1 (en) Pharmaceutical compound and preparation method therefor and use thereof
US20260027056A1 (en) High surface-area lyophilized compositions comprising arsenic for oral administration in patients
HK40129981A (en) High surface-area lyophilized compositions comprising arsenic for oral administration in patients
HK40073108A (en) High surface-area lyophilized compositions comprising arsenic for oral administration in patients
HK1248113B (zh) 用於在患者中口服施用的含有砷的高表面积冻干组合物
Kaur et al. Colon Specific Matrix tablets of Oxaliplatin combined with Curcumin: Development and Evaluation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200616

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210326

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210609

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210621

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210621

R150 Certificate of patent or registration of utility model

Ref document number: 6928768

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350